Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Ettinger

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Managed Care Interface|January 13, 2006
Making the most of managed care dollars spent for postmenopausal osteoporosisBruce Ettinger
Menopause (New York, N.Y.)|August 16, 2008
A personal perspective on fracture risk assessment toolsBruce Ettinger
Maturitas|March 27, 2007
Rationale for use of lower estrogen doses for postmenopausal hormone therapyBruce Ettinger
Maturitas|March 14, 2007
Tibolone for prevention and treatment of postmenopausal osteoporosisBruce Ettinger
The American Journal of Medicine|January 18, 2006
Vasomotor symptom relief versus unwanted effects: role of estrogen dosageBruce Ettinger
Managed Care (Langhorne, Pa.)|June 21, 2005
Bisphosphonates: providing strength to a significant classBruce Ettinger
Managed Care (Langhorne, Pa.)|June 21, 2008
Appropriate intervention through fracture risk assessmentBruce Ettinger
Journal of the American Geriatrics Society|May 7, 2020
How Should We Counsel Asian Americans about Fracture Risk?Joan C Lo, Bruce Ettinger
The Journal of Clinical Endocrinology and Metabolism|March 13, 2002
For osteoporosis, are two antiresorptive drugs better than one?Bruce Ettinger, John P Bilezikian
Menopause (New York, N.Y.)|October 26, 2018
Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedulesBruce Ettinger, De-Kun Li, Raymond Klein
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Managed Care Interface|January 13, 2006
Making the most of managed care dollars spent for postmenopausal osteoporosisBruce Ettinger
Menopause (New York, N.Y.)|August 16, 2008
A personal perspective on fracture risk assessment toolsBruce Ettinger
Maturitas|March 27, 2007
Rationale for use of lower estrogen doses for postmenopausal hormone therapyBruce Ettinger
Maturitas|March 14, 2007
Tibolone for prevention and treatment of postmenopausal osteoporosisBruce Ettinger
The American Journal of Medicine|January 18, 2006
Vasomotor symptom relief versus unwanted effects: role of estrogen dosageBruce Ettinger
Managed Care (Langhorne, Pa.)|June 21, 2005
Bisphosphonates: providing strength to a significant classBruce Ettinger
Managed Care (Langhorne, Pa.)|June 21, 2008
Appropriate intervention through fracture risk assessmentBruce Ettinger
Journal of the American Geriatrics Society|May 7, 2020
How Should We Counsel Asian Americans about Fracture Risk?Joan C Lo, Bruce Ettinger
The Journal of Clinical Endocrinology and Metabolism|March 13, 2002
For osteoporosis, are two antiresorptive drugs better than one?Bruce Ettinger, John P Bilezikian
Menopause (New York, N.Y.)|October 26, 2018
Continuation of postmenopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedulesBruce Ettinger, De-Kun Li, Raymond Klein
Pageof 6